Gannet BioChem completed the acquisition of Laysan Bio.

Gannet BioChem, a specialty CDMO specializing in the development, scaling, and manufacturing of polyethylene glycol reagents for therapeutic products, completed the acquisition of Laysan Bio, a biotechnology company specializing in the development and supply of activated polyethylene glycol reagents for therapeutic, medical device, and research applications. Financial terms were not disclosed. “This acquisition meaningfully expands our technical depth and manufacturing flexibility across activated polymers and bioconjugation. Laysan Bio’s experience, talent, and customer relationships align closely with Gannet BioChem’s mission. Together, we are building a more comprehensive platform to support partners from discovery through commercial manufacturing,” Nicholas Shackley, Gannet BioChem CEO.